title: [Pegylated interferon beta 1a. A new therapy option for treatment of relapsing-remitting multiple sclerosis].
abstract: Pegylation of pharmacological substances was developed in the 1970s as a way of improving their efficacy and elimination and hence reducing the dosage frequency. A prominent example is pegylation of IFNα, which revolutionized the treatment of virus hepatitis in the late 1990s. Efforts have now succeeded in producing a pegylated interferon beta (PEG-IFN-β1a) to treat multiple sclerosis (MS) and the efficacy and safety have been investigated in a phase III trial called the ADVANCE study. The 1-year results of this randomized, double blind, multicenter, placebo-controlled study in more than 1500 MS patients show that administration of subcutaneous PEG-IFN-β1a significantly reduces the annual relapse rate and disability progression. The safety and tolerability profile of PEG-IFN-β1a was found to be similar to that of conventional IFN-β drugs. The most common adverse events were flu-like symptoms and redness at the injection site. The results of this study underscore that PEG-IFN-β1a is an interesting new therapeutic option in the treatment of relapsing-remitting MS that combines highly effective interferon with the established tolerability and safety profile of IFN-β at a reduced dosage frequency.
authors.affiliation: Neurologische[Symbol: see text]Klinik,[Symbol: see text]Medizinische Fakultät, Universitätsklinikum Düsseldorf, Heinrich-Heine-Universität, Moorenstr. 5, 40225, Düsseldorf, Deutschland.
authors.forename: V I
authors.initials: VI
authors.lastname: Leussink
authors.forename: C
authors.initials: C
authors.lastname: Warnke
authors.forename: B
authors.initials: B
authors.lastname: Tackenberg
authors.forename: H
authors.initials: H
authors.lastname: Wiendl
authors.forename: B C
authors.initials: BC
authors.lastname: Kieseier
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000328:Adult; D004311:Double-Blind Method; D005260:Female; D005858:Germany; D006801:Humans; D007279:Injections, Subcutaneous; D000068556:Interferon beta-1a / Q000008:administration & dosage*; D008297:Male; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000175:diagnosis* / Q000188:drug therapy*; D015990:Placebo Effect; D016896:Treatment Outcome
chemical_list: D000276:Adjuvants, Immunologic; D000068556:Interferon beta-1a
references.citation: J Pharmacol Exp Ther. 2011 Sep;338(3):984-96
references.pmid: 21690216
references.citation: BMC Neurol. 2014 Dec 31;14:240
references.pmid: 25551571
references.citation: J Pharmacol Exp Ther. 2001 Jun;297(3):1059-66
references.pmid: 11356929
references.citation: Biologics. 2013;7:131-8
references.pmid: 23807836
references.citation: Curr Pharm Des. 2002;8(24):2139-57
references.pmid: 12369859
references.citation: J Clin Pharmacol. 2012 Jun;52(6):798-808
references.pmid: 21680782
references.citation: CNS Drugs. 2012 Mar 1;26(3):205-14
references.pmid: 22201341
references.citation: Bioconjug Chem. 2006 Jan-Feb;17(1):179-88
references.pmid: 16417267
references.citation: J Control Release. 2012 Jul 20;161(2):461-72
references.pmid: 22094104
references.citation: Expert Opin Emerg Drugs. 2009 Jun;14(2):363-80
references.pmid: 19453284
references.citation: Pharm Res. 2005 Jan;22(1):58-61
references.pmid: 15771230
references.citation: Expert Opin Drug Deliv. 2009 Jan;6(1):1-16
references.pmid: 19236204
references.citation: J Interferon Cytokine Res. 2010 Oct;30(10):777-85
references.pmid: 20836711
references.citation: Crit Rev Ther Drug Carrier Syst. 2008;25(5):403-47
references.pmid: 19062633
references.citation: Lancet Neurol. 2014 Jul;13(7):657-65
references.pmid: 24794721